Effect of Farnesol on Staphylococcus aureus Biofilm Formation and Antimicrobial Susceptibility
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Staphylococcus aureus is among the leading pathogens causing bloodstream infections able to form biofilms on host tissue and indwelling medical devices and to persist and cause disease. Infections caused by S. aureus are becoming more difficult to treat because of increasing resistance to antibiotics. In a biofilm environment particularly, microbes exhibit enhanced resistance to antimicrobial agents. Recently, farnesol was described as a quorum-sensing molecule with possible antimicrobial properties. In this study, the effect of farnesol on methicillin-resistant and -susceptible strains of S. aureus was investigated. With viability assays, biofilm formation assessment, and ethidium bromide uptake testing, farnesol was shown to inhibit biofilm formation and compromise cell membrane integrity. The ability of farnesol to sensitize S. aureus to antimicrobials was assessed by agar disk diffusion and broth microdilution methods. For both strains of staphylococci, farnesol was only able to reverse resistance at a high concentration (150 μM). However, it was very successful at enhancing the antimicrobial efficacy of all of the antibiotics to which the strains were somewhat susceptible. Therefore, synergy testing of farnesol and gentamicin was performed with static biofilms exposed to various concentrations of both agents. Plate counts of harvested biofilm cells at 0, 4, and 24 h posttreatment indicated that the combined effect of gentamicin at 2.5 times the MIC and farnesol at 100 μM (22 μg/ml) was able to reduce bacterial populations by more than 2 log units, demonstrating synergy between the two antimicrobial agents. This observed sensitization of resistant strains to antimicrobials and the observed synergistic effect with gentamicin indicate a potential application for farnesol as an adjuvant therapeutic agent for the prevention of biofilm-related infections and promotion of drug resistance reversal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms
Donlan, R. M., & Costerton, J. W. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.2.167-193.2002 · Cited by 6,644 · cited 1×
“This sessile mode of life provides biofilm-embedded microbes with ample environmental nutrients and protection from host phagocytic clearance, greatly limiting the ability of the host to adequately deal with the infection (14, 18).”
BackgroundAntibiotic resistance of bacteria in biofilms
Stewart, P. S., & William Costerton, J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05321-1 · Cited by 4,585
Biofilms: Microbial Life on Surfaces
Donlan, R. M. (2002) · Emerging Infectious Diseases · doi:10.3201/eid0809.020063 · Cited by 4,145
Microbial Biofilms: from Ecology to Molecular Genetics
Davey, M. E., & O'toole, G. A. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.4.847-867.2000 · Cited by 3,086
The Changing Epidemiology of Staphylococcus aureus?
Chambers, H. F. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010204 · Cited by 1,495
Mechanisms of antibiotic resistance in bacterial biofilms
Stewart, P. S. (2002) · International Journal of Medical Microbiology · doi:10.1078/1438-4221-00196 · Cited by 1,385
Candida biofilms and their role in infection
Douglas, L. J. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(02)00002-1 · Cited by 1,150
Nickel, J. C., Ruseska, I., Wright, J. B., & Costerton, J. W. (1985) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.27.4.619 · Cited by 889
Cited by
Lebeaux, D., Ghigo, J.-M., & Beloin, C. (2014) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00013-14 · Cited by 1,318
Phytochemicals for human disease: An update on plant-derived compounds antibacterial activity
Barbieri, R., Coppo, E., Marchese, A., Daglia, M., Sobarzo-Sánchez, E., Nabavi, S. F., & Nabavi, S. M. (2017) · Microbiological Research · doi:10.1016/j.micres.2016.12.003 · Cited by 669
Medically important bacterial-fungal interactions
Peleg, A. Y., Hogan, D. A., & Mylonakis, E. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2313 · Cited by 619
Genetic control of Candida albicans biofilm development
Finkel, J. S., & Mitchell, A. P. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2475 · Cited by 612
Plant Natural Products Targeting Bacterial Virulence Factors
Silva, L. N., Zimmer, K. R., Macedo, A. J., & Trentin, D. S. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00184 · Cited by 504
Angane, M., Swift, S., Huang, K., Butts, C. A., & Quek, S. Y. (2022) · Foods · doi:10.3390/foods11030464 · Cited by 484
Innate and Induced Resistance Mechanisms of Bacterial Biofilms
Anderson, G. G., & O'Toole, G. A. (2008) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-75418-3_5 · Cited by 438
“Another molecule that interferes with S. aureus biofilm formation is farnesol, produced by Candida albicans ( Jabra-Rizk et al. 2006 ).”
BackgroundQuorum sensing in fungi – a review
Albuquerque, P., & Casadevall, A. (2012) · Medical Mycology · doi:10.3109/13693786.2011.652201 · Cited by 431
Richard, M. L., & Sokol, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0121-2 · Cited by 406
Cross-kingdom interactions:Candida albicans and bacteria
Shirtliff, M. E., Peters, B. M., & Jabra-Rizk, M. A. (2009) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2009.01668.x · Cited by 400
Self-citationHorev, B., Klein, M. I., Hwang, G., Li, Y., Kim, D., Koo, H., & Benoit, D. S. W. (2015) · ACS Nano · doi:10.1021/nn507170s · Cited by 340
Farnesol, a common sesquiterpene, inhibits PQS production in Pseudomonas aeruginosa
Cugini, C., Calfee, M. W., Farrow, J. M., Morales, D. K., Pesci, E. C., & Hogan, D. A. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05840.x · Cited by 332
Kong, E. F., Tsui, C., Kucharíková, S., Andes, D., Van Dijck, P., & Jabra-Rizk, M. A. (2016) · mBio · doi:10.1128/mbio.01365-16 · Cited by 294
Self-citationSchlecht, L. M., Peters, B. M., Krom, B. P., Freiberg, J. A., Hänsch, G. M., Filler, S. G., Jabra-Rizk, M. A., & Shirtliff, M. E. (2015) · Microbiology · doi:10.1099/mic.0.083485-0 · Cited by 281
Self-citationFungal Biofilms, Drug Resistance, and Recurrent Infection
Desai, J. V., Mitchell, A. P., & Andes, D. R. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019729 · Cited by 252
“Jabra-Rizk et al. (2006) have shown that farnesol inhibits S. aureus biofilm formation, thus this fungal quorum-sensing molecule impacts both Gram-negative and -positive bacteria.”
BackgroundGenetic control of bacterial biofilms
Wolska, K. I., Grudniak, A. M., Rudnicka, Z., & Markowska, K. (2016) · Journal of Applied Genetics · doi:10.1007/s13353-015-0309-2 · Cited by 154
Sharifi, A., Mohammadzadeh, A., Zahraei Salehi, T., & Mahmoodi, P. (2018) · Journal of Applied Microbiology · doi:10.1111/jam.13639 · Cited by 111
Candida species in cystic fibrosis: A road less travelled
Chotirmall, S. H., Greene, C. M., & McElvaney, N. G. (2010) · Medical Mycology · doi:10.3109/13693786.2010.503320 · Cited by 61
“aureus to a variety of clinically important antibiotics (58).”
Background
Metadata
- Authors
- Jabra-Rizk, M. A., Meiller, T. F., James, C. E., & Shirtliff, M. E.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2006-04
- Volume
- 50
- Issue
- 4
- Pages
- 1463-1469
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2170241476
- Cited by
- 341
- References
- 43
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.